Novoprotein(SH:688137) Xin Lang Cai Jing·2025-09-26 03:52Group 1 - The stock price of Nearshore Protein increased by 5.22% to 43.56 CNY per share, with a trading volume of 23.61 million CNY and a turnover rate of 1.71%, resulting in a total market capitalization of 3.057 billion CNY [1] - Nearshore Protein Technology Co., Ltd. was established on September 7, 2009, and went public on September 29, 2022. The company specializes in the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with providing related technical services [1] - The revenue composition of Nearshore Protein includes: target and factor proteins (58.04%), enzymes and reagents (25.63%), CRO services (11.87%), recombinant antibodies (2.67%), and other (1.79%) [1] Group 2 - Among the top ten circulating shareholders of Nearshore Protein, a fund under Rongtong Fund holds 500,000 shares, unchanged from the previous period, representing 1.53% of the circulating shares, with an estimated floating profit of approximately 1.08 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a latest scale of 2.074 billion CNY. Year-to-date returns are 18.29%, ranking 4813 out of 8171 in its category, while the one-year return is 38.27%, ranking 4040 out of 8004 [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 34 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 149.47% and the worst being -18.43% [3]